The Momentum Phase 2 Obesity Trial is currently closed for enrollment and is not accepting new participants at this time.
The study was designed to evaluate whether ALT-801 (also called pemvidutide, the proposed INN name for this drug) can safely induce weight loss in people with excess weight or obesity. It also assessed quality of life and improvement in other conditions associated with excess weight and obesity, such as high blood pressure, high cholesterol, and predisposition to diabetes.
Study participants may be able to join the trial if they meet the following requirements*:
* Other study requirements will apply, as will be explained by the study doctor at the study site
Participation in the Momentum study lasts about 13 months. Study participants can expect the following:
Participation in a clinical study is voluntary. You can ask any questions you have and may leave the study at any time, for any reason.
Visit clinicaltrials.gov to learn more about the Momentum Obesity Trial.